androgel 16,2 mg/g gel
besins healthcare - testosteronenantat - gel - 16,2 mg/g
nebido 1000 mg/dosis injektionsvæske, opløsning
orifarm a/s - testosteronundecanoat - injektionsvæske, opløsning - 1000 mg/dosis
leuprorelin "sandoz" 3,6 mg implantat, fyldt injektionssprøjte
sandoz a/s - leuprorelinacetat - implantat, fyldt injektionssprøjte - 3,6 mg
leuprorelin "sandoz" 5 mg implantat, fyldt injektionssprøjte
sandoz a/s - leuprorelinacetat - implantat, fyldt injektionssprøjte - 5 mg
lutrate depot 3,75 mg pulver og solvens til depotinjektionsvæske, suspension
gp-pharm s.a. - leuprorelinacetat - pulver og solvens til depotinjektionsvæske, suspension - 3,75 mg
firmagon
ferring pharmaceuticals a/s - degarelix - prostatiske neoplasmer - endokrine terapi - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
andriol 40 mg kapsler, bløde
orifarm a/s - testosteronundecanoat - kapsler, bløde - 40 mg
degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostatiske neoplasmer - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
camcevi
accord healthcare s.l.u. - leuprorelin mesilate - prostatiske neoplasmer - endokrine terapi - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
zytiga
janssen-cilag international n.v. - abiraterone acetat - prostatiske neoplasmer - endokrine terapi - zytiga er angivet med prednison eller prednisolon for:behandling af metastatisk kastration resistent prostatakræft hos voksne mænd, der er asymptomatiske eller mildt symptomatisk efter svigt af androgen deprivation terapi i hvem kemoterapi er endnu ikke klinisk indicatedthe behandling af metastatisk kastration resistent prostatakræft hos voksne mænd, hvis sygdommen har udviklet sig på eller efter en docetaxel-baseret kemoterapi.